MedTrace Logo

Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone

NCT00458796 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2022-05-27

No results posted yet for this study

Summary

RATIONALE: Zoledronic acid may help decrease the risk of broken bones, bone pain, and other symptoms caused by bone metastases. It may also help patients live more comfortably.

PURPOSE: This randomized clinical trial is studying different schedules of zoledronic acid to compare how well they work in treating patients with breast cancer that has spread to the bone.

Conditions

Interventions

DRUG

zoledronic acid

PROCEDURE

quality-of-life assessment

Sponsors & Collaborators

  • University of Sheffield

    collaborator OTHER

  • University of Leeds

    lead OTHER

Principal Investigators

  • Robert E. Coleman, MD, FRCP · Cancer Research Centre at Weston Park Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00458796 on ClinicalTrials.gov